Article
Oncology
Rachel G. Woodford, Deborah D. X. Zhou, Peey-Sei Kok, Sally J. Lord, Michael Friedlander, Ian C. Marschner, R. John Simes, Chee Khoon Lee
Summary: Overall survival (OS) is the gold standard endpoint for oncology trials, but progression-free survival 2 (PFS-2) has been proposed as a surrogate endpoint due to delays in OS data maturation. A meta-analysis found that PFS-2 had a moderate correlation with OS across diverse tumors and therapies, performing consistently better than PFS-1 and objective response rate (ORR). PFS-2 should be included as a key endpoint in future randomized trials of solid tumors.
Article
Hematology
Jesse G. Dixon, Natalie Dimier, Tina Nielsen, Jamie Zheng, Robert Marcus, Franck Morschhauser, Andrew M. Evens, Massimo Federico, Kristie A. Blum, Qian Shi
Summary: This study aimed to evaluate the surrogate role of PET-CR measured at the end of the induction period as a predictor of PFS in first-line follicular lymphoma treatment. The results showed that although EoI-PET-CR demonstrated strong predictive ability for PFS at a prognostic level, the trial-level assessment did not show a strong correlation. The high uncertainty in estimation was possibly due to the small number of trials and limited availability of PET data. Maintenance therapy may have influenced the association between treatment effects. Further evaluation of PET-CR as a surrogate endpoint is still warranted.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
Chen Hu, Meihua Wang, Cai Wu, Heng Zhou, Cong Chen, Scott Diede
Summary: This study suggests that using restricted mean duration of response (DOR) in randomized phase 2 trials may be more sensitive and helpful than progression-free survival (PFS) and objective response rate (ORR) in estimating subsequent phase 3 conclusions, potentially complementing decision-making in future clinical development.
Article
Oncology
Fatima Tensaouti, Franck Desmoulin, Julia Gilhodes, Margaux Roques, Soleakhena Ken, Jean -Albert Lotterie, Georges Noel, Gilles Truc, Marie -Pierre Sunyach, Marie Charissoux, Nicolas Magne, Vincent Lubrano, Patrice Peran, Elizabeth Cohen-Jonathan Moyal, Anne Laprie
Summary: This study aimed to identify different components of glioblastoma subtypes using a large MRSI dataset and determine their association with progression-free survival. The results showed that pre-radiotherapy MRSI can reveal tumor heterogeneity and clusters with metabolic abnormalities and high lactate are predictive of PFS.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Pauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, Maxime Fontanilles, Christelle Levy, Alessandro Adriano Viansone, Audrey Mailliez, Marc Debled, Anthony Goncalves, Fanny Le Du, Florence Lerebours, Jean-Marc Ferrero, Jean-Christophe Eymard, Marie-Ange Mouret-Reynier, Thierry Petit, Jean-Sebastien Frenel, Florence Dalenc, Coralie Courtinard, Marie Chaix, Thomas Bachelot
Summary: The study found that PFS under first endocrine therapy appeared similar whether prescribed before or after chemotherapy in treating HR+/HER2- metastatic breast cancer, suggesting chemotherapy does not promote endocrine resistance.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Yushan Jia, Shuai Quan, Jialiang Ren, Hui Wu, Aishi Liu, Yang Gao, Fene Hao, Zhenxing Yang, Tong Zhang, He Hu
Summary: This study assessed the predictive value of magnetic resonance imaging (MRI) radiomics for progression-free survival (PFS) in patients with prostate cancer (PCa). The results showed that the hybrid model constructed from radiomics and clinical data performed the best in predicting PFS. This model provides a non-invasive diagnostic tool for risk stratification of clinical patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Yixuan Zhai, Jiwei Bai, Mingxuan Li, Shuai Wang, Chuzhong Li, Xinting Wei, Yazhuo Zhang
Summary: The study aimed to establish and validate a prognostic nomogram for predicting progression-free survival (PFS) in chordoma patients. By analyzing the expression levels of biomarkers, the researchers confirmed clinical factors and biomarkers associated with PFS.
JOURNAL OF NEUROSURGERY
(2021)
Review
Health Care Sciences & Services
Kristin Levoy, Suzanne S. Sullivan, Jesse Chittams, Ruth L. Myers, Susan E. Hickman, Salimah H. Meghani
Summary: This meta-analysis investigates the association between advance care planning (ACP) and end-of-life (EOL) care outcomes in cancer patients. The results show that ACP is associated with a reduced likelihood of aggressive EOL care, such as chemotherapy, intensive care, hospital admissions, and hospital death, while increasing the odds of do-not-resuscitate orders.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
(2023)
Article
Management
David Chen, Christopher S. Tang, Huihui Wang, Rowan Wang, Yimin Yu
Summary: This study proposes a proactive upgrade policy for selling products with different feature combinations, allowing free upgrades before products go out of stock to secure future sales. The optimal proactive upgrade strategy is governed by two state-dependent thresholds, and can significantly create value over the reactive upgrade policy when the next-price-level product has similar consumer utility or the price sensitivity is intermediate.
M&SOM-MANUFACTURING & SERVICE OPERATIONS MANAGEMENT
(2022)
Article
Oncology
Anushka Walia, Jordan Tuia, Vinay Prasad
Summary: Composite outcome measures are commonly used in oncology research, but they have limitations such as vague definitions and complicated result comparisons. Knowing the breakdown of component events is essential for accurate interpretation of trial results and assessing the true benefit of interventions.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Jamie Garside, Qin Shen, Bernd Westermayer, Michiel van de Ven, Sonja Kroep, Viktor Chirikov, Ingolf Juhasz-Boess
Summary: This study found a strong correlation between progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) in the first-line treatment of advanced/recurrent endometrial cancer. Improvements in PFS/TTP are likely to translate into subsequent improvements in OS.
CLINICAL THERAPEUTICS
(2023)
Article
Oncology
Marco Rossi, Lorenzo Gay, Federico Ambrogi, Marco Conti Nibali, Tommaso Sciortino, Guglielmo Puglisi, Antonella Leonetti, Cristina Mocellini, Manuela Caroli, Susanna Cordera, Matteo Simonelli, Federico Pessina, Piera Navarria, Andrea Pace, Riccardo Soffietti, Roberta Ruda, Marco Riva, Lorenzo Bello
Summary: The study found that supratotal resection is strongly associated with good oncological outcomes in molecularly defined lower-grade gliomas, regardless of molecular subtypes and grading.
Review
Oncology
Johannes Wach, Martin Vychopen, Andreas Kuehnapfel, Clemens Seidel, Erdem Gueresir
Summary: This study conducted a systematic review and meta-analysis on the impact of supramarginal resection (SMR) on progression-free survival (PFS) and postoperative complications. The results suggest that SMR may improve PFS without increasing surgical complications. However, more research is needed to confirm these findings.
Review
Environmental Studies
Niall Kerr, Mark Winskel
Summary: The rapid phase-out of fossil fuel home heating technologies poses a significant policy challenge. Drawing on international experiences of technology phase-out across different sectors and countries, this study aims to provide insights for the phase-out of fossil fuel technologies in the home heating sector, with a focus on the UK. The study identifies various factors that influence technology phase-out, including cost and performance, infrastructure and system context, public engagement and acceptability, incumbent interests, and policy design. By acknowledging both differences and similarities, a more robust approach to analogous reasoning can be applied in policy and research.
ENERGY RESEARCH & SOCIAL SCIENCE
(2022)
Article
Ophthalmology
Felipe A. Medeiros, Alessandro A. Jammal
Summary: The purpose of this study was to investigate whether changes in standard automated perimetry (SAP) mean deviation (MD) over the initial 2-year follow-up period could predict events of visual field progression. The study followed 246 eyes of 168 glaucoma patients for up to 5 years and found that the rate of SAP MD change during the first 2 years was strongly predictive of subsequent visual field progression. These findings provide support for using the slope of MD change as a suitable endpoint for measuring progression in clinical trials.
